186 related articles for article (PubMed ID: 16181238)
41. Polycystic ovary syndrome and hyperprolactinemia are distinct entities.
Filho RB; Domingues L; Naves L; Ferraz E; Alves A; Casulari LA
Gynecol Endocrinol; 2007 May; 23(5):267-72. PubMed ID: 17558684
[TBL] [Abstract][Full Text] [Related]
42. [The effect of neoplastic hyperprolactinemia on bone density].
Baldelli R; Perrone G; Nardone MR; Galoppi P; Provenzano A; Fabbrini A; Rocco A
Minerva Endocrinol; 1996 Mar; 21(1):7-11. PubMed ID: 8786742
[TBL] [Abstract][Full Text] [Related]
43. Ropinirole for the Treatment of Hyperprolactinemia: A Dose-Escalation Study of Efficacy and Tolerability.
Heneghan LJ; Tsang A; Dimino C; Khandji AG; Panigrahi SK; Page-Wilson G
J Clin Endocrinol Metab; 2024 Jan; 109(2):e667-e674. PubMed ID: 37715962
[TBL] [Abstract][Full Text] [Related]
44. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
Colao A; Pivonello R; Rosato F; Tita P; De Menis E; Barreca A; Ferrara R; Mainini F; Arosio M; Lombardi G
Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447
[TBL] [Abstract][Full Text] [Related]
45. Lack of tumor reduction in hyperprolactinemic women with extrasellar macroadenomas treated with bromocriptine.
Boulanger CM; Mashchak CA; Chang RJ
Fertil Steril; 1985 Oct; 44(4):532-5. PubMed ID: 4054327
[TBL] [Abstract][Full Text] [Related]
46. [Amenorrhoea and hyperprolactinaemia (author's transl)].
Tscherne G
Wien Klin Wochenschr; 1979 Dec; 91(23):790-3. PubMed ID: 543141
[TBL] [Abstract][Full Text] [Related]
47. Risk factors for secondary amenorrhea and galactorrhea.
Gold EB; Bush T; Chee E
Int J Fertil Menopausal Stud; 1994; 39(3):177-84. PubMed ID: 7920755
[TBL] [Abstract][Full Text] [Related]
48. Long-term basal and dynamic evaluation of hypothalamic-pituitary-adrenal (HPA) axis in acromegalic patients.
Ronchi CL; Ferrante E; Rizzo E; Giavoli C; Verrua E; Bergamaschi S; Lania AG; Beck-Peccoz P; Spada A
Clin Endocrinol (Oxf); 2008 Oct; 69(4):608-12. PubMed ID: 18410544
[TBL] [Abstract][Full Text] [Related]
49. Hyperprolactinaemia and pituitary adenomas in adolescence.
Dissaneevate P; Warne GL
J Pediatr Endocrinol Metab; 1998; 11(4):531-41. PubMed ID: 9777574
[TBL] [Abstract][Full Text] [Related]
50. Surgical management of pediatric Cushing's disease.
Das NK; Lyngdoh BT; Bhakri BK; Behari S; Bhatia V; Jain VK; Banerji D
Surg Neurol; 2007 Mar; 67(3):251-7; discussion 257. PubMed ID: 17320630
[TBL] [Abstract][Full Text] [Related]
51. [Bromocriptine treatment of invasive giant prolactinomas prior to comprehensive treatments: results of a long-term follow up].
Zhang HW; Yu CJ; Sun W; Yang J; Yan CX; Cun EH
Zhonghua Wai Ke Za Zhi; 2006 Nov; 44(22):1555-7. PubMed ID: 17359664
[TBL] [Abstract][Full Text] [Related]
52. Prolactinomas: surgical therapy, indications and results.
Rawe SE; Williamson HO; Levine JH; Phansey SA; Hungerford D; Adkins WY
Surg Neurol; 1980 Sep; 14(3):161-7. PubMed ID: 7434180
[TBL] [Abstract][Full Text] [Related]
53. Morphologic changes of prolactin-producing pituitary adenomas after short treatment with dopamine agonists.
Kontogeorgos G; Horvath E; Kovacs K; Coire C; Lloyd RV; Scheithauer BW; Smyth HS
Acta Neuropathol; 2006 Jan; 111(1):46-52. PubMed ID: 16328513
[TBL] [Abstract][Full Text] [Related]
54. [The origin of hyperprolactinemia associated with infertility and its treatment with Bromocriptin-Richter tablets].
Farkas M; Tárczy C; Tóth E
Acta Pharm Hung; 1991 Sep; 61(5):262-76. PubMed ID: 1785356
[TBL] [Abstract][Full Text] [Related]
55. Endoscopic transsphenoidal treatment in recurrent and residual pituitary adenomas--first experience.
Rudnik A; Zawadzki T; Gałuszka-Ignasiak B; Bazowski P; Duda I; Wojtacha M; Rudnik AI; Krawczyk I
Minim Invasive Neurosurg; 2006 Feb; 49(1):10-4. PubMed ID: 16547875
[TBL] [Abstract][Full Text] [Related]
56. [Macroadenoma of the pituitary gland with moderate hyperprolactinaemia].
Harms E; Siggelkow H; Buchfelder M; Saeger W; Hüfner M
Dtsch Med Wochenschr; 2003 Mar; 128(13):667-70. PubMed ID: 12660899
[TBL] [Abstract][Full Text] [Related]
57. The choice of therapy in acromegaly: results of treatment at a tertiary care hospital.
Isidro ML; Castro JA; Penín M; Armenta J; Cordido F
Neuro Endocrinol Lett; 2008 Dec; 29(6):1038-44. PubMed ID: 19112390
[TBL] [Abstract][Full Text] [Related]
58. Treatment for prolactinomas and hyperprolactinaemia: a lifetime approach.
Mann WA
Eur J Clin Invest; 2011 Mar; 41(3):334-42. PubMed ID: 20955213
[TBL] [Abstract][Full Text] [Related]
59. [Transsphenoidal microsurgical results of non-invasive prolactinomas].
Xu ZQ; Su CB; Ren ZY; Wang RZ; Yang Y; Ma WB; Li YN; Xing B; Lian W; Yang Z
Zhonghua Wai Ke Za Zhi; 2008 Feb; 46(4):293-5. PubMed ID: 18683769
[TBL] [Abstract][Full Text] [Related]
60. [Long-term surgical results of microprolactinomas].
Hirohata T; Uozumi T; Mukada K; Arita K; Kurisu K; Yano T; Takechi A; Onda J
No Shinkei Geka; 1991 Oct; 19(10):951-6. PubMed ID: 1944780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
